GLUCO-SCAN
Financiado
Deuterium labeling of GLUCOse improves magnetic resonance imaging Sensitivity to...
Deuterium labeling of GLUCOse improves magnetic resonance imaging Sensitivity to CANcer metabolism
The targeted scientific breakthrough of GLUCO-SCAN is the development and clinical evaluation of a disruptive whole-body molecular imaging concept for cancer assessment. The only currently established whole-body molecular imaging...
The targeted scientific breakthrough of GLUCO-SCAN is the development and clinical evaluation of a disruptive whole-body molecular imaging concept for cancer assessment. The only currently established whole-body molecular imaging device is positron emission tomography (PET). Glucose (Glc)-sensitive PET is widely used in cancer diagnosis and treatment assessment, but has several major limitations: PET involves harmful ionizing radiation, is expensive, not widely available, and cannot differentiate between cancer-specific and normal cellular glucose uptake. These limitations prohibit an even more widespread use of PET, e.g. for screening. We propose a new Magnetic Resonance Imaging (MRI) concept, whole-body deuterium metabolic imaging (DMI) that will overcome these limitations.Deuteration is a simple chemical procedure with which it is possible to artificially label a broad range of molecules with an equally broad range of potential applications, e.g., targeting Glc metabolism in cancer. After ingestion, this labeled Glc is metabolized in cells and the label is transferred to all metabolic products, which can be tracked by DMI.Building on our recent preliminary results in Nature Biomed, we propose a combination of novel MRI hardware, dynamic spectroscopic data sampling, deep learning algorithms, and a clinical validation to answer the following three research questions in a 5-year project:(i) Is DMI a viable alternative for whole-body cancer assessment?(ii) How is DMI positioned compared to Glc-sensitive PET?(iii) Can DMI be performed on widely available MRI systems and simultaneous with standard MRI?GLUCO-SCAN will fill a gap in current medical imaging by offering an alternative for whole-body PET examinations and potentially even for screening of high risk populations. Ultimately, it will pave the way for a new generation of MR scanners with all-in-one whole-body imaging capability that would capture morphologic and molecular information simultaneously.
ver más
Duración del proyecto: 59 meses
Fecha Inicio: 2023-12-01
Fecha Fin: 2028-11-30
Fecha Fin: 2028-11-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-12-01
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2022-COG:
ERC CONSOLIDATOR GRANTS
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
MEDIZINISCHE UNIVERSITAET WIEN
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5